Australia: Innovators to be hardest hit by PBS Access and Sustainability Package

Last Updated: 7 June 2015
Article by Natalie Shoolman

Most Read Contributor in Australia, November 2017

Innovator pharmaceutical companies will be the hardest hit from the statutory price reductions, price disclosure changes and the speed with which generic drugs can obtain Pharmaceutical Benefits Scheme listing, brought about by implementation of the Government's PBS Access and Sustainability Package.

Elements of the new Package require amendments to be made to the National Health Act 1953. The proposed amendments are contained in the National Health Amendment (Pharmaceutical Benefits) Bill 2015, which was introduced into Parliament on 27 May 2015. According to the Government, the Package will:

  • enable net savings to Government of more than $3.7 billion over five years; and
  • ensure ongoing access to innovative medicines through a sustainable PBS.

Key amendments to the National Health Act

Statutory price reduction for drugs on the F1 formulary

The Bill proposes a one-off 5% statutory price reduction for all forms and strengths of a drug on the F1 formulary after the drug has been listed on the F1 formulary for five years.

The first reduction day will be 1 April 2016 and the last reduction day will be 1 April 2020.

The Government has clarified that the reduction takes no account of when the drug was listed for extension of indications, only the date on which the drug was first listed. This means that indications that were listed more recently will also bear the 5% price cut.

Price disclosure arrangements for drugs on the F2 formulary

The Bill provides that price disclosure arrangements for multiple-brand medicines that have been listed on the F2 formulary for three years or more will be changed to remove the originator brand from calculation of the weighted average disclosed price. More than one brand may be designated as an originator brand. The first reduction day will be 1 October 2016. This is likely to push weighted average disclosed price down and lead to greater price disclosure percentage reductions for multi-brand medicines on the F2 formulary.

Flow-on price disclosure reductions

The Bill proposes to apply flow-on price disclosure reductions for listed component drugs to multiple brand combination medicines on the F2 formulary. This process will commence on 1 April 2016, with a back-capture day on 1 October 2016 to flow-on any outstanding prior price disclosure reductions for component drugs to multiple-brand combination medicines. This will close a "loophole" which has allowed some companies to avoid price reductions of component medicines by listing a second brand of their own combination drug.

Price reductions on biosimilar listing

The proposed amendments remove uncertainty as to whether the first listing of a biosimilar will cause a 16% price reduction and movement of the biosimilar and its reference product to the F2 formulary. If passed, the amendments confirm that such a 16% price reduction will occur and the biosimilar and reference product will be listed on the F2 formulary. This will give companies greater certainty about the pricing consequences of biosimilar listing.

Proposed changes which affect generic listing and biosimilars

The Government's Package also includes the first ever strategic agreement with the Generic Medicines Industry Association which provides, amongst other matters, for:

  • an increase in the number of dates when new brands with price flow-on effects can be listed from three to six times a year, which will bring first generic products to market quicker;
  • substitution of biosimilars at the pharmacy level based on PBAC recommendations.

Less time for innovators, faster process for generics

The doubling of the number of listing dates for the first generic drug with price-flow on effects means that the time period between the first generic obtaining registration on the Australian Register of Therapeutic Goods and the generic obtaining PBS listing will be reduced. Innovator companies will therefore have less time to make a decision whether to apply for a preliminary injunction to protect any intellectual property rights they have relating to the drug prior to the generic obtaining listing on the PBS.

Further, if proceedings are commenced for patent infringement and a preliminary injunction is obtained by the innovator company which is discharged at the final hearing, the generic company will be able to get its PBS listing and be on the market in a much shorter time period than is currently the case.

Flagging of biosimilar products for substitution

It will be interesting to see how recommendations of PBAC on the flagging of biosimilar products for substitution with the reference biological medicine at the pharmacy level are applied. Generic companies have been lobbying for substitution and extrapolation across indications.

PBAC has advised that this flagging would occur where the data are supportive of such a conclusion. When establishing that a biosimilar product could be flagged with the originator product, PBAC says it will consider:

  • absence of data to suggest significant differences in clinical effectiveness or safety compared with the originator product;
  • absence of identified populations where the risks of using the biosimilar product are disproportionately high;
  • availability of data to support switching between the originator product and the biosimilar product;
  • availability of data for treatment-naďve patients initiating on the biosimilar product; and
  • whether the Therapeutic Goods Administration has deemed a product to be biosimilar with the originator product.

Where a biosimilar product could not be flagged at the time of PBS listing, PBAC says data should be collected to support flagging at a later point.

PBAC's intention to look at the absence of data regarding difference in clinical effectiveness or safety compared with the originator product and absence of identified populations at risk from substituting with biosimilar product is particularly problematic as these are negative stipulations. They do not require positive proof of no adverse difference in effectiveness, safety or special risk etc., but rather rely on the absence of data identifying any such issues. This may give rise to safety concerns if the data are absent because no studies have been done for a particular comparator.

Next steps

The Bill is listed in Parliament's indicative programme for further debate before the House of Representatives on 3 June 2015. Should the amendments to the National Health Act pass through both Houses of Parliament and be implemented together with the other aspects of the Government's Package, innovators will need to:

  • carefully consider the impact of pricing changes on forecasts;
  • re-evaluate the timelines for seeking preliminary injunctive relief for patent infringement; and
  • may also wish to approach PBAC to discuss how it will be assessing the absence of data when determining whether a biosimilar can be flagged for substitution.

Clayton Utz communications are intended to provide commentary and general information. They should not be relied upon as legal advice. Formal legal advice should be sought in particular transactions or on matters of interest arising from this bulletin. Persons listed may not be admitted in all states and territories.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions